Aethlon Medical Inc (AEMD) 6.85 $AEMD
Aethlon Medical Extends Contract with the Defense Advanced Research Projects Agency
PR Newswire - Mon Sep 28, 1:45PM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it has entered into an extension of its contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. The Company originally entered into the initial DARPA contract on September 30, 2011. DARPA entered into this contract extension in order to exercise its option to continue the contract for year five, the final year of the contract.
AEMD: 6.85 (+0.07)
Financial Report Card - Report on Aethlon Medical
PR Newswire - Wed Sep 16, 7:05AM CDT
ACI Association has initiated research coverage on Aethlon Medical, Inc. (NASDAQ: AEMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Fiscal 2016 First Quarter Results
PR Newswire - Thu Aug 13, 3:05PM CDT
Aethlon Medical, Inc. (Nasdaq:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the first quarter of fiscal 2016 ended June 30, 2015.
AEMD: 6.85 (+0.07)
Aethlon Medical (AEMD) CEO Note: Nasdaq listing, equity financing and therapeutic pipeline expansion
PR Newswire - Thu Aug 06, 8:00AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.85 (+0.07)
Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015
PR Newswire - Mon Aug 03, 8:00AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its First Quarter Fiscal 2016 investor conference call and webcast on Thursday, August 13, 2015 at 4:30 p.m. Eastern Time.
AEMD: 6.85 (+0.07)
Aethlon Medical, Inc. (Nasdaq: AEMD) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jul 23, 9:00AM CDT
What:
AEMD: 6.85 (+0.07), NDAQ: 53.09 (-0.69)
Aethlon Medical to Ring the Nasdaq Stock Market Closing Bell on July 24th
PR Newswire - Tue Jul 21, 8:00AM CDT
Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company will ring the Nasdaq Stock Market closing bell on Friday, July 24, 2015 in honor of its recent listing on the Nasdaq Capital Market. Attending the event on behalf of Aethlon Medical will be Jim Joyce, Chairman and Chief Executive Officer and Jim Frakes, Chief Financial Officer.
AEMD: 6.85 (+0.07)
Aethlon Medical Begins Trading on the Nasdaq Capital Market
PR Newswire - Mon Jul 13, 8:40AM CDT
Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's common stock commenced trading on the Nasdaq Capital Market under the symbol "AEMD" at the opening of trading today.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Nasdaq Capital Market Listing Approval
PR Newswire - Wed Jul 08, 8:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.
AEMD: 6.85 (+0.07)
Aethlon Medical enters into USD6m equity investment agreement
M2 - Thu Jun 25, 6:06AM CDT
Biofiltration devices company Aethlon Medical (Other OTC:AEMD) revealed on Wednesday the launch of USD6m stock purchase agreement.
AEMD: 6.85 (+0.07)
Aethlon Medical raises $6M in private placement
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:22AM CDT
AEMD: 6.85 (+0.07)
Aethlon Medical Announces $6 Million Equity Investment
PR Newswire - Wed Jun 24, 7:07AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement. The per share purchase price was $6.30, which includes a five-year warrant that entitles the holder to purchase up to three common shares for each four shares purchased in the offering. The share purchase price underlying each warrant is also $6.30.
AEMD: 6.85 (+0.07)
Aethlon Medical Discloses Upcoming Presentations
PR Newswire - Thu Jun 11, 8:05AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that its President Rod Kenley will give a presentation on June 12th at the 33rd Annual Vicenza Course on Critical Care Nephrology being held at the Fiera di Vicenza Convention Center in Vicenza Italy. Mr. Kenley's presentation is entitled, "A Case Study using Lectin-Affinity Plasmapheresis in the Treatment of Ebola Virus Disease." On June 16th, Mr. Kenley will be giving a presentation entitled, "Lectin-Affinity Plasmapheresis for the Extracorporeal Extraction of Pathogenic Viruses and Exosomes" at Goethe University in Frankfurt, Germany.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements
PR Newswire - Tue Jun 09, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that in order to support the Company's application to list on the Nasdaq Capital Market, Dr. Richard Tullis resigned from Aethlon's Board of Directors effective June 5, 2015. Under Nasdaq Corporate Governance Rule 5605(b), a listed company's Board of Directors is required to have a majority of independent directors. Prior to the resignation of Dr. Tullis, Aethlon's Board was comprised of an equal number of inside and outside directors. Dr. Tullis will continue in his position as the Company's Chief Science Officer.
AEMD: 6.85 (+0.07)
Aethlon Medical to Present at the BIO International Convention
PR Newswire - Fri Jun 05, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that Chairman and CEO Jim Joyce will give a corporate presentation at the BIO International Convention on Thursday, June 18th in Philadelphia. The presentation is scheduled to begin at 10:00 AM ET in Theater 2 at the Pennsylvania Convention Center.
AEMD: 6.85 (+0.07)
Aethlon Medical Expands Clinical Research Studies to Include Chikungunya Virus
PR Newswire - Thu Jun 04, 7:35AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. In late 2013, Chikungunya was identified for the first time in the Americas on islands in the Caribbean. Since then, transmission of the virus has been identified in 44 countries or territories throughout the Americas with more than 1.2 million suspected cases reported to the Pan American Health Organization.
AEMD: 6.85 (+0.07)
Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference
PR Newswire - Tue May 26, 8:15AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual Microcap Investor Conference on Thursday, May 28th. Details of Aethlon Medical's presentation are as follows:
AEMD: 6.85 (+0.07)
SeeThruEquity Issues Update Note on Aethlon Medical, Inc. (OTCQB: AEMD)
ACCESSWIRE - Fri May 15, 8:01AM CDT
Update Note Focuses on Company's Announcement of Reverse Stock Split and Adjusts Target Price to $26.00
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
AEMD: 6.85 (+0.07)
Aethlon Medical Extends Contract with the Defense Advanced Research Projects Agency
PR Newswire - Mon Sep 28, 1:45PM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it has entered into an extension of its contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. The Company originally entered into the initial DARPA contract on September 30, 2011. DARPA entered into this contract extension in order to exercise its option to continue the contract for year five, the final year of the contract.
AEMD: 6.85 (+0.07)
Financial Report Card - Report on Aethlon Medical
PR Newswire - Wed Sep 16, 7:05AM CDT
ACI Association has initiated research coverage on Aethlon Medical, Inc. (NASDAQ: AEMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Fiscal 2016 First Quarter Results
PR Newswire - Thu Aug 13, 3:05PM CDT
Aethlon Medical, Inc. (Nasdaq:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the first quarter of fiscal 2016 ended June 30, 2015.
AEMD: 6.85 (+0.07)
Aethlon Medical (AEMD) CEO Note: Nasdaq listing, equity financing and therapeutic pipeline expansion
PR Newswire - Thu Aug 06, 8:00AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.85 (+0.07)
Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015
PR Newswire - Mon Aug 03, 8:00AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its First Quarter Fiscal 2016 investor conference call and webcast on Thursday, August 13, 2015 at 4:30 p.m. Eastern Time.
AEMD: 6.85 (+0.07)
Aethlon Medical, Inc. (Nasdaq: AEMD) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jul 23, 9:00AM CDT
What:
AEMD: 6.85 (+0.07), NDAQ: 53.09 (-0.69)
Aethlon Medical to Ring the Nasdaq Stock Market Closing Bell on July 24th
PR Newswire - Tue Jul 21, 8:00AM CDT
Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company will ring the Nasdaq Stock Market closing bell on Friday, July 24, 2015 in honor of its recent listing on the Nasdaq Capital Market. Attending the event on behalf of Aethlon Medical will be Jim Joyce, Chairman and Chief Executive Officer and Jim Frakes, Chief Financial Officer.
AEMD: 6.85 (+0.07)
Aethlon Medical Begins Trading on the Nasdaq Capital Market
PR Newswire - Mon Jul 13, 8:40AM CDT
Aethlon Medical, Inc. (NASDAQ:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's common stock commenced trading on the Nasdaq Capital Market under the symbol "AEMD" at the opening of trading today.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Nasdaq Capital Market Listing Approval
PR Newswire - Wed Jul 08, 8:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.
AEMD: 6.85 (+0.07)
Aethlon Medical enters into USD6m equity investment agreement
M2 - Thu Jun 25, 6:06AM CDT
Biofiltration devices company Aethlon Medical (Other OTC:AEMD) revealed on Wednesday the launch of USD6m stock purchase agreement.
AEMD: 6.85 (+0.07)
Aethlon Medical raises $6M in private placement
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:22AM CDT
AEMD: 6.85 (+0.07)
Aethlon Medical Announces $6 Million Equity Investment
PR Newswire - Wed Jun 24, 7:07AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement. The per share purchase price was $6.30, which includes a five-year warrant that entitles the holder to purchase up to three common shares for each four shares purchased in the offering. The share purchase price underlying each warrant is also $6.30.
AEMD: 6.85 (+0.07)
Aethlon Medical Discloses Upcoming Presentations
PR Newswire - Thu Jun 11, 8:05AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that its President Rod Kenley will give a presentation on June 12th at the 33rd Annual Vicenza Course on Critical Care Nephrology being held at the Fiera di Vicenza Convention Center in Vicenza Italy. Mr. Kenley's presentation is entitled, "A Case Study using Lectin-Affinity Plasmapheresis in the Treatment of Ebola Virus Disease." On June 16th, Mr. Kenley will be giving a presentation entitled, "Lectin-Affinity Plasmapheresis for the Extracorporeal Extraction of Pathogenic Viruses and Exosomes" at Goethe University in Frankfurt, Germany.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements
PR Newswire - Tue Jun 09, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that in order to support the Company's application to list on the Nasdaq Capital Market, Dr. Richard Tullis resigned from Aethlon's Board of Directors effective June 5, 2015. Under Nasdaq Corporate Governance Rule 5605(b), a listed company's Board of Directors is required to have a majority of independent directors. Prior to the resignation of Dr. Tullis, Aethlon's Board was comprised of an equal number of inside and outside directors. Dr. Tullis will continue in his position as the Company's Chief Science Officer.
AEMD: 6.85 (+0.07)
Aethlon Medical to Present at the BIO International Convention
PR Newswire - Fri Jun 05, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that Chairman and CEO Jim Joyce will give a corporate presentation at the BIO International Convention on Thursday, June 18th in Philadelphia. The presentation is scheduled to begin at 10:00 AM ET in Theater 2 at the Pennsylvania Convention Center.
AEMD: 6.85 (+0.07)
Aethlon Medical Expands Clinical Research Studies to Include Chikungunya Virus
PR Newswire - Thu Jun 04, 7:35AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. In late 2013, Chikungunya was identified for the first time in the Americas on islands in the Caribbean. Since then, transmission of the virus has been identified in 44 countries or territories throughout the Americas with more than 1.2 million suspected cases reported to the Pan American Health Organization.
AEMD: 6.85 (+0.07)
Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference
PR Newswire - Tue May 26, 8:15AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual Microcap Investor Conference on Thursday, May 28th. Details of Aethlon Medical's presentation are as follows:
AEMD: 6.85 (+0.07)
SeeThruEquity Issues Update Note on Aethlon Medical, Inc. (OTCQB: AEMD)
ACCESSWIRE - Fri May 15, 8:01AM CDT
Update Note Focuses on Company's Announcement of Reverse Stock Split and Adjusts Target Price to $26.00
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
AEMD: 6.85 (+0.07)
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
AEMD: 6.85 (+0.07)
